Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on mhc class i following transduction

Molecular Therapy

Volumn 18, Issue 1, 2010, Pages 135-142

  Finn, Jonathan D ^a   Hui, Daniel ^a   Downey, Harre D ^a   Dunn, Danielle ^a   Pien, Gary C ^a   Mingozzi, Federico ^a   Zhou, Shangzhen ^a   High, Katherine A ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; BORTEZOMIB; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARVOVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ANIMALS; ANTIGEN PRESENTATION; BORONIC ACIDS; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DEPENDOVIRUS; GENES, MHC CLASS I; GENETIC VECTORS; HEMOPHILIA B; HUMANS; MICE; PROTEASE INHIBITORS; PYRAZINES; TRANSDUCTION, GENETIC;

MIRIDAE; MUS;

EID: 74149089236     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.257     Document Type: Article

References (43)

1. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and effcacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
2. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
3. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
4. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
5. Pien, GC, Basner-Tschakarjan, E, Hui, DJ, Mentlik, AN, Finn, JD, Hasbrouck, NC et al. (2009). Capsid antigen presentation fags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 119: 1688-1695.
6. Ling, YH, Liebes, L, Zou, Y and Perez-Soler, R (2003). Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723.
7. Alexandrova, A, Petrov, L, Georgieva, A, Kirkova, M and Kukan, M (2008). Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell Biochem Funct 26: 392-398.
8. Fribley, A, Zeng, Q and Wang, CY (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24: 9695-9704.
9. Groettrup, M and Schmidtke, G (1999). Selective proteasome inhibitors: modulators of antigen presentation? Drug Discov Today 4: 63-71.
10. Duan, D, Yue, Y, Yan, Z, Yang, J and Engelhardt, JF (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 105: 1573-1587.
11. Denby, L, Nicklin, SA and Baker, AH (2005). Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther 12: 1534-1538.
12. Jennings, K, Miyamae, T, Traister, R, Marinov, A, Katakura, S, Sowders, D et al. (2005). Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther 11: 600-607.
13. Yan, Z, Zak, R, Luxton, GW, Ritchie, TC, Bantel-Schaal, U and Engelhardt, JF (2002). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction effciency of recombinant vectors. J Virol 76: 2043-2053.
14. Douar, AM, Poulard, K, Stockholm, D and Danos, O (2001). Intracellular traffcking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 75: 1824-1833.
15. Johnson, JS and Samulski, RJ (2009). Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83: 2632-2644.
16. Van Kaer, L, Ashton-Rickardt, PG, Ploegh, HL and Tonegawa, S (1992). TAP1 mutant mice are defcient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 71: 1205-1214.
17. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422.
18. Scholten, KB, Schreurs, MW, Ruizendaal, JJ, Kueter, EW, Kramer, D, Veenbergen, S et al. (2005). Preservation and redirection of HPV16E7-specifc T cell receptors for immunotherapy of cervical cancer. Clin Immunol 114: 119-129.
19. Joseph, A, Zheng, JH, Follenzi, A, Dilorenzo, T, Sango, K, Hyman, J et al. (2008). Lentiviral vectors encoding human immunodefciency virus type 1 (HIV-1)-specifc T-cell receptor genes effciently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specifc inhibitory activity. J Virol 82: 3078-3089.
20. Yan, Z, Zak, R, Zhang, Y, Ding, W, Godwin, S, Munson, K et al. (2004). Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 78: 2863-2874.
21. Nathwani, AC, Cochrane, M, McIntosh, J, Ng, CY, Zhou, J, Gray, JT et al. (2009). Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther 16: 60-69.
22. Bai, A and Forman, J (1997). The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol 159: 2139-2146.
23. Shi, J, Tricot, GJ, Garg, TK, Malaviarachchi, PA, Szmania, SM, Kellum, RE et al. (2008). Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111: 1309-1317.
24. Ding, WX, Ni, HM, Gao, W, Yoshimori, T, Stolz, DB, Ron, D et al. (2007). Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171: 513-524.
25. Arias, IM, Jakoby, WB, Popper, H, Schachter, D and Shafritz, DA (1988). The Liver: Biology and Pathology, 2nd edn. Raven Press: New York. p 1405.
26. Wu, J (2002). On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2: 904-912.
27. Cui, H, Matsui, K, Omura, S, Schauer, SL, Matulka, RA, Sonenshein, GE et al. (1997). Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA 94: 7515-7520.
28. Wang, X, Luo, H, Chen, H, Duguid, W and Wu, J (1998). Role of proteasomes in T cell activation and proliferation. J Immunol 160: 788-801.
29. Berges, C, Haberstock, H, Fuchs, D, Miltz, M, Sadeghi, M, Opelz, G et al. (2008). Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124: 234-246.
30. Nencioni, A, Garuti, A, Schwarzenberg, K, Cirmena, G, Dal Bello, G, Rocco, I et al. (2006). Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36: 681-689.
31. Nencioni, A, Grunebach, F, Patrone, F, Ballestrero, A and Brossart, P (2006). The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 26: 487-498.
32. Luo, H, Wu, Y, Qi, S, Wan, X, Chen, H and Wu, J (2001). A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72: 196-202.
33. Wu, Y, Han, B, Luo, H, Shi, G and Wu, J (2004). Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection. Transplantation 78: 360-366.
34. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specifc T cells. Blood 114: 2077-2086.
35. Mingozzi, F and High, KA (2007). Immune responses to AAV in clinical trials. Curr Gene Ther 7: 316-324.
36. Wang, J, Xie, J, Lu, H, Chen, L, Hauck, B, Samulski, RJ et al. (2007). Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA 104: 13104-13109.
37. Papa, L, Gomes, E and Rockwell, P (2007). Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis 12: 1389-1405.
38. Sanlioglu, S and Engelhardt, JF (1999). Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Ther 6: 1427-1437.
39. Murphy, SL, Bhagwat, A, Edmonson, S, Zhou, S and High, KA (2008). High-throughput screening and biophysical interrogation of hepatotropic AAV. Mol Ther 16: 1960-1967.
40. Thomas, CE, Storm, TA, Huang, Z and Kay, MA (2004). Rapid uncoating of vector genomes is the key to effcient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78: 3110-3122.
41. Grimm, D, Zhou, S, Nakai, H, Thomas, CE, Storm, TA, Fuess, S et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102: 2412-2419.
42. Clayton, RF, Rinaldi, A, Kandyba, EE, Edward, M, Willberg, C, Klenerman, P et al. (2005). Liver cell lines for the study of hepatocyte functions and immunological response. Liver Int 25: 389-402.
43. Walter, J, You, Q, Hagstrom, JN, Sands, M and High, KA (1996). Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci USA 93: 3056-3061.